Basic health insurance plans in China will begin this year to cover the cost of most drugs used to treat rare diseases, according to a National Healthcare Security Administration statement released in December. Under the plan, rare disease drugs that are proven... Read More
Twenty-nine new drugs produced by Chinese pharmaceutical companies were added to the new National Drug Reimbursement List (NRDL) in January, squeezing out foreign competitors, whose offerings were deemed by review panels to be exorbitantly priced. The success of such a relatively large... Read More
China, Korea, Taiwan, and Japan are rapidly becoming world leaders in cell and gene therapy research and innovation, fueled by significant public and private investment and streamlined regulations that are spurring breakthroughs in the field. All three countries have long been leaders... Read More
Chinese regulators are clamping down on sweetheart deals between drug and medical device manufacturers and hospitals, in an effort to deter corruption that they fear undercuts the quality of the country’s healthcare. Among the actions taken in recent months are legal proceedings... Read More
Moving to standardize and improve the quality of medical devices utilized at health care centers throughout China, the country’s National Healthcare Security Administration is establishing a value-based purchasing platform for the submission and purchase of medical devices. The platform, expected to be... Read More
To shorten the amount of time needed for clinical trials of crucially-needed drugs, regulators in China in November issued a draft of technical guidelines to grant conditional approval of critical new treatments. In short, early-phase clinical data can be used to get... Read More
Stepping up its commitment to researching the potential of cells harvested from human embryos, China has announced plans to construct what it says will be the largest stem cell technology laboratory in Asia. China sees the development of stem cell and regenerative... Read More
This article was originally published on MedTech Intelligence. With patients and medical providers across Asia and around the world forced by the global pandemic to rely on online platforms more than ever before, the medical device industry is finding itself uniquely vulnerable... Read More
Qualified research institutions that develop their own pharmaceuticals will be eligible to hold marketing authorization permits in China under new legal guidance that went into effect in late September. Since 2015, when China first began implementing its Marketing Authorization Holder (MAH) system,... Read More
Sales of diagnostic mammography equipment in the Asia-Pacific region is expected to rise significantly over the next eight years, according to two recently published studies. The reports by Globalcan and GlobalData vary in their specific findings. But both project compound annual growth... Read More